Last updated: February 12, 2026
What Are the Patentability Criteria for Biopharmaceuticals in Israel?
Israel's patent law aligns with international standards, requiring that biopharmaceutical inventions meet novelty, inventive step, and industrial applicability.
-
Novelty: An invention must not have been disclosed publicly before the filing date. Prior disclosures include scientific publications, previous patent applications in Israel or abroad, or public use.
-
Inventive Step: The invention must not be obvious to a person skilled in the field. Israel's Patent Office (ILPO) applies a medium- to high-threshold standard, considering the state of the art.
-
Industrial Applicability: The invention must be capable of being used in industry, a criterion straightforward for biopharmaceuticals.
Additional Requirements:
-
Disclosure: The application must sufficiently disclose the invention to enable replication. For biopharmaceuticals, this involves detailed descriptions of production methods, sequences, and testing data.
-
Definition of Patentable Subject Matter: Israel excludes certain biological materials from patentability if they occur naturally. However, isolated, purified, or genetically modified biopharmaceuticals qualify as patentable inventions.
Are There Patentability Barriers Unique to Biopharmaceuticals in Israel?
Yes. The Israel Patent Law imposes specific restrictions:
-
Biological Materials: Naturally occurring biological materials are not patentable unless isolated or purified. For example, naturally occurring DNA sequences are generally excluded unless claimed as engineered or synthetic.
-
Methods of Treatment: Methods related to medical or surgical treatment are often not patentable per se but can be claimed if formulated as products or manufacturing processes.
-
Use Claims: Claims specific to a new use of an existing compound are patentable, provided the use is novel and inventive.
-
Clarity and Sufficient Disclosure: For complex biopharmaceuticals, the patent application must include comprehensive experimental data and detailed sequence disclosures.
Enforceability of Biopharmaceutical Patents in Israel
Israel's enforcement framework revolves around patent validity and infringing activity.
-
Patent Validity: Validity is challenged through opposition or invalidity proceedings in the District Courts or the Patent Office. Validity challenges often focus on obviousness, prior disclosures, and subject matter patentability.
-
Infringement: Infringement involves unauthorized manufacture, use, or sale of the patented invention. Enforceability depends on a clear claim construction and demonstration of infringement. Proof often requires detailed technical evidence, especially for biopharmaceuticals.
-
Patent Term: The standard patent term is 20 years from the filing date. Data exclusivity or supplementary protection remains under review and varies based on international agreements.
Scope of Claims in Biopharmaceutical Patent Applications
-
Product Claims: Encompass the isolated or recombinant molecules, such as DNA, RNA, proteins, or antibodies. These claims often specify sequences or structures.
-
Method Claims: Cover processes for producing or using the biopharmaceutical, including manufacturing methods, purification processes, or methods of treatment.
-
Use Claims: Protect specific therapeutic applications or indications of the biopharmaceuticals, even if the compound itself is known.
-
Formulation Claims: Cover specific compositions, formulations, or delivery mechanisms, such as drug-depot systems or sustained-release formulations.
-
Markush Claims: Often employed to cover a range of variants, such as different sequences or chemical modifications.
Claim Drafting Strategies
-
Focus on broad product claims, including various sequences or formulations, to maximize scope.
-
Include multiple dependent claims to specify embodiments, covering various uses, formulations, and manufacturing methods.
-
Clearly define sequences and structural features to prevent invalidation based on claim ambiguity.
Patent Office Practices and Policy Trends
-
Examination Process: Typically takes 2-3 years, with patentability assessed under the Israeli Patent Law and applicable international treaties.
-
Patentability Examination: Emphasizes inventive step and novelty, with particular scrutiny on biological sequences and methods involving natural materials.
-
Patent Opposition: May be filed within 3 months of grant, citing prior art or lack of inventive step.
-
Recent Policy Trends: Increased focus on biopharmaceutical patentability, aligning with global standards, and careful review of claims related to natural biological materials.
Summarized Comparative Insights
| Aspect |
Israel Patent Office |
International Norms |
| Patentability of biological materials |
Isolated or purified biological materials qualify; natural occurences do not |
Similar; some jurisdictions broaden scope with biotech exemptions |
| Data Disclosure Requirements |
Detailed sequences, production methods, and test data required |
Similar; bio-specific disclosures emphasized |
| Patent Term |
20 years from filing |
20 years; some adjust for patent term extension |
| Enforcement |
Validity challenged via courts; infringement proven with technical evidence |
Similar enforcement mechanisms; evidence pivotal |
Key Takeaways
-
Patentability hinges on novelty, inventive step, and industrial applicability. Complex biological sequences require detailed disclosures and carefully drafted claims.
-
Enforceability depends on validity validation and infringement proof, often necessitating technical evidence for biopharmaceuticals.
-
Scope of claims should be broad but precise, including product, method, and use claims. Draft claims to cover variants and formulations to maximize protection.
-
Israel aligns closely with international standards but emphasizes detailed disclosures and cautious claim drafting, particularly concerning natural biological materials.
FAQs
Q1: Can naturally occurring genes be patented in Israel?
A: Generally, no. Isolated or purified genes may qualify if they involve inventive activity, but naturally occurring genes are excluded unless modified or engineered.
Q2: How long does patent examination typically take in Israel?
A: Approximately 2-3 years from filing to decision, depending on the complexity and workload.
Q3: What types of claims offer the broadest protection for biopharmaceuticals?
A: Product claims covering the isolated molecule, use claims for therapeutic indications, and formulation claims for specific delivery methods.
Q4: Are method of treatment claims patentable in Israel?
A: No. Such claims are generally excluded; protection is granted through product or process claims related to manufacturing.
Q5: What are common challenges in enforcing biopharmaceutical patents in Israel?
A: Proving infringement requires detailed technical evidence, and defending validity may involve opposition procedures focusing on inventive step and prior disclosures.
Citations:
- Israeli Patent Law, 5727-1967, as amended.
- Israel Patent Office Official Guidelines.
- WIPO Patent Information, Patentability of Biotechnological Inventions, 2022.
- European Patent Office, Biotechnology Examination Guidelines, 2022.
- US Patent and Trademark Office, Guide to Biotechnology Patent Practice, 2021.
